Humacyte

Historical price data

Humacyte is transforming regenerative medicine with its proprietary platform for developing acellular, bioengineered human tissues designed to be universally implantable without immune rejection. The company achieved a landmark FDA approval in December 2024 for Symvess™ for vascular trauma and is advancing a broad pipeline targeting vascular access, coronary artery disease, and complex organ replacement. Led by founder and renowned physician-scientist Dr. Laura Niklason, Humacyte aims to address a wide range of injuries and chronic conditions with its off-the-shelf, regenerative tissue products.

A scalable bioengineering platform that creates acellular, universally implantable human tissues from human cells. The proprietary process involves decellularization to remove immunogenic components, resulting in off-the-shelf, regenerative scaffolds that the patient's body can repopulate.

11 drugs in pipeline, 4 in Phase 3

Total raised: $690M

Humacyte competes with synthetic grafts (e.g., Gore-Tex) and autologous vein grafts in vascular surgery. Its key differentiation is offering a universally implantable, off-the-shelf, regenerative biologic vessel that becomes living tissue and shows low infection rates—a profile not matched by existing synthetic or biologic alternatives.